Trial · NCT03305809
Results by group159
Each measurement the trial posted, group by group, in the words and numbers it posted.
81 to 100 of 159
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | Placebo | -0.32 | Standard Error 0.976 | Units on a scale | |
| Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | 10 mg LY3154207 | 0.23 | Standard Error 0.961 | Units on a scale | |
| Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | 30 mg LY3154207 | 2.09 | Standard Error 1.018 | Units on a scale | |
| Change From Baseline in the Penn Parkinson's Daily Activities Questionnaire-15 (PDAQ-15) Total Score | 75 mg LY3154207 | 1.24 | Standard Error 1.128 | Units on a scale | |
| Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | Placebo | -0.19 | Standard Error 0.280 | Units on a scale | |
| Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | 10 mg LY3154207 | 0.44 | Standard Error 0.271 | Units on a scale | |
| Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | 30 mg LY3154207 | 0.88 | Standard Error 0.292 | Units on a scale | |
| Change From Baseline in Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test Score | 75 mg LY3154207 | 0.30 | Standard Error 0.325 | Units on a scale | |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | Placebo | Motor Experiences of Daily Living | 0.28 | Standard Error 0.656 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | 10 mg LY3154207 | Motor Experiences of Daily Living | -1.45 | Standard Error 0.649 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | 30 mg LY3154207 | Motor Experiences of Daily Living | -2.08 | Standard Error 0.700 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | 75 mg LY3154207 | Motor Experiences of Daily Living | -3.22 | Standard Error 0.779 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | Placebo | Motor Exam | -0.12 | Standard Error 1.343 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | 10 mg LY3154207 | Motor Exam | -3.39 | Standard Error 1.240 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | 30 mg LY3154207 | Motor Exam | -3.40 | Standard Error 1.331 | Units on a scale |
| Change in MDS-UPDRS Parts II (Motor Experiences of Daily Living) and III (Motor Exam) From Baseline to Week 12 | 75 mg LY3154207 | Motor Exam | -4.35 | Standard Error 1.434 | Units on a scale |
| Number of Participants Who Met the Potentially Clinically Significant Vital Signs Criteria at 3 Consecutive Time Points at Visit 3 | Placebo | 0 | Participants | ||
| Number of Participants Who Met the Potentially Clinically Significant Vital Signs Criteria at 3 Consecutive Time Points at Visit 3 | 10 mg LY3154207 | 0 | Participants | ||
| Number of Participants Who Met the Potentially Clinically Significant Vital Signs Criteria at 3 Consecutive Time Points at Visit 3 | 30 mg LY3154207 | 1 | Participants | ||
| Number of Participants Who Met the Potentially Clinically Significant Vital Signs Criteria at 3 Consecutive Time Points at Visit 3 | 75 mg LY3154207 | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03305809/results?page=5